Sharyn D Baker Selected Research

troxacitabine

4/2006	Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
5/2002	Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days.
2/2002	Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.
1/2002	Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sharyn D Baker Research Topics

Disease

64	Neoplasms (Cancer) 03/2022 - 01/2002
20	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 05/2008
10	Leukemia 01/2022 - 02/2002
10	Neutropenia 01/2013 - 05/2002
7	Breast Neoplasms (Breast Cancer) 01/2021 - 06/2003
6	Exanthema (Rash) 12/2019 - 05/2002
6	Febrile Neutropenia 08/2017 - 09/2003
5	Diarrhea 05/2011 - 05/2002
4	Prostatic Neoplasms (Prostate Cancer) 10/2010 - 08/2006
3	Hypoxia (Hypoxemia) 01/2022 - 01/2018
3	Glioma (Gliomas) 06/2013 - 04/2005
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2006 - 01/2006
3	Thrombocytopenia (Thrombopenia) 02/2006 - 05/2002
2	Acute Kidney Injury (Acute Renal Failure) 12/2021 - 01/2020
2	Drug-Related Side Effects and Adverse Reactions 09/2020 - 07/2006
2	Carcinogenesis 01/2020 - 10/2009
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 08/2017 - 08/2013
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 08/2017 - 01/2011
2	Nausea 05/2011 - 08/2006
2	Mucositis 09/2008 - 05/2002
1	Cardiotoxicity 01/2021
1	Hepatocellular Carcinoma (Hepatoma) 01/2020
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2020
1	Liver Neoplasms (Liver Cancer) 01/2020
1	Acute Megakaryoblastic Leukemia (Leukemia, Megakaryocytic) 01/2019
1	Oncogene Addiction 01/2018
1	Pain (Aches) 09/2017
1	Hypokalemia 08/2017

Drug/Important Bio-Agent (IBA)

15	Docetaxel (Taxotere)FDA Link 08/2012 - 09/2003
12	Pharmaceutical PreparationsIBA 12/2020 - 01/2003
10	Sorafenib (BAY 43-9006)FDA Link 01/2022 - 05/2008
9	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2021 - 03/2011
8	NucleosidesIBA 01/2021 - 01/2002
6	Phosphotransferases (Kinase)IBA 01/2020 - 06/2011
6	Imatinib Mesylate (Gleevec)FDA Link 02/2014 - 08/2006
5	DNA (Deoxyribonucleic Acid)IBA 03/2011 - 12/2004
5	Gefitinib (Iressa)FDA Link 03/2007 - 05/2005
4	Tyrosine Kinase InhibitorsIBA 01/2022 - 03/2007
4	Proteins (Proteins, Gene)FDA Link 01/2020 - 08/2003
4	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2013 - 07/2006
4	Paclitaxel (Taxol)FDA LinkGeneric 08/2012 - 01/2003
4	Irinotecan (Camptosar)FDA LinkGeneric 03/2008 - 08/2003
4	ErbB Receptors (EGF Receptor)IBA 03/2007 - 07/2006
4	troxacitabineIBA 04/2006 - 01/2002
4	Cytochrome P-450 CYP3AIBA 10/2005 - 08/2003
4	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 10/2005 - 08/2003
3	crenolanibIBA 01/2022 - 11/2013
3	Organic Cation Transporter 1IBA 01/2020 - 05/2008
3	Messenger RNA (mRNA)IBA 01/2020 - 12/2004
3	fms-Like Tyrosine Kinase 3IBA 11/2019 - 10/2013
3	Sunitinib (Sutent)FDA Link 10/2013 - 05/2008
3	Transaminases (Aminotransferases)IBA 05/2011 - 08/2006
2	gilteritinibIBA 01/2022 - 12/2021
2	ibrutinibIBA 11/2021 - 01/2020
2	Agammaglobulinaemia Tyrosine KinaseIBA 11/2021 - 01/2020
2	Biological ProductsIBA 11/2021 - 03/2011
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 06/2007
2	Bevacizumab (Avastin)FDA Link 12/2019 - 01/2013
2	Clofarabine (Clolar)FDA Link 12/2019 - 08/2011
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2019 - 01/2013
2	Glucuronosyltransferase (UDP Glucuronosyltransferase)IBA 01/2019 - 08/2003
2	Etoposide (VP 16)FDA LinkGeneric 08/2017 - 04/2012
2	Dasatinib (BMS 354825)FDA Link 08/2013 - 06/2013
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2013 - 06/2007
2	4-phenylbutyric acid (Buphenyl)FDA Link 10/2009 - 04/2005
2	Azacitidine (5 Azacytidine)FDA Link 10/2009 - 12/2004
2	AndrogensIBA 06/2008 - 08/2006
2	7-hydroxystaurosporine (UCN 01)IBA 03/2008 - 01/2005
2	Temozolomide (Temodar)FDA LinkGeneric 06/2007 - 01/2004
2	Pemetrexed (MTA)FDA Link 02/2006 - 01/2006
2	dimethyl benzoylphenyl ureaIBA 06/2004 - 11/2003
2	TubulinIBA 06/2004 - 11/2003
2	Polysorbates (PSML)FDA Link 01/2004 - 10/2003
2	docosahexaenoyl-paclitaxelIBA 09/2003 - 01/2003
1	venetoclaxIBA 03/2022
1	VemurafenibIBA 12/2021
1	Proto-Oncogene Proteins B-rafIBA 12/2021
1	nilotinib FDA Link 01/2021
1	CytidineIBA 01/2021
1	Calcium-Binding ProteinsIBA 01/2021
1	dubermatinibIBA 12/2020
1	ElectrolytesIBA 01/2020
1	Syk KinaseIBA 01/2020
1	src-Family KinasesIBA 01/2020
1	AnionsIBA 01/2019
1	UridineIBA 01/2019
1	regorafenibIBA 01/2019
1	Peptides (Polypeptides)IBA 01/2019
1	Janus Kinase InhibitorsIBA 01/2019
1	GlucuronidesIBA 01/2019
1	ElementsIBA 08/2018
1	Oxygen (Dioxygen)IBA 08/2018
1	Opioid Analgesics (Opioids)IBA 09/2017
1	plerixafor FDA Link 08/2017
1	XenobioticsIBA 01/2017
1	Interleukin-3 Receptor alpha SubunitIBA 11/2016

Therapy/Procedure

19	Therapeutics 01/2022 - 01/2004
5	Drug Therapy (Chemotherapy) 08/2017 - 08/2003
3	Drug Tapering 01/2020 - 02/2006
2	Castration 10/2010 - 06/2008